The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome
Abstract
Objective: We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high‐density lipoprotein (HDL) subfractions and plasma pre‐beta1‐HDL levels in overweight and obese subjects with metabolic syndrome (MetS). Methods: Patients (n = 89) were prescribed a low‐fat low‐calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200 mg/day (F group) or both (OF group) for 6 months. HDL subfractions were determined using a polyacrylamide gel tube electrophoresis method and pre‐beta1‐HDL levels using enzyme‐linked immunoabsorbent assay. Results: We observed a significant change of high‐density lipoprotein cholesterol (HDL‐C) levels only in the F group (+3%, p < 0.05). Large HDL‐C levels were significantly increased and small HDL‐C levels were significantly reduced with O administration. In F group we observed a significant increase of small HDL‐C levels. No significant change of large or small HDL‐C levels was observed with combination treatment. We observed a significant increase of pre‐beta1‐HDL levels in all groups, which was significantly greater in OF group compared with O or F monotherapy. Conclusion: OF combination increased the antiatherogenic pre‐beta1‐HDL levels in overweight and obese patients with MetS. Furthermore, OF combination counterbalanced the reduction of small HDL‐C levels observed with orlistat monotherapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fenofibrate treatment typically reduces serum triglycerides by a mean change of −93.7 mg/dL (−39.3%), increases high density lipoprotein cholesterol by +5.5 mg/dL (+12.4%), and reduces low density lipoprotein cholesterol by −17.9 mg/dL (−12.3%).
“Typical changes in serum lipids as a result of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of −93.7 mg/dL (−39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by −17.9 mg/dL (−12.3%).”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [39]
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026 · see citing works
High Density Lipoproteins and Arteriosclerosis
von Eckardstein, A., Nofer, J., & Assmann, G. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.1.13 · Cited by 696 · see citing works
Otvos, J. D., Collins, D. E., Freedman, D. S., SHALAUROVA, I. Y., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 542 · see citing works
Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress
Kontush, A., Chantepie, S., & Chapman, M. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000091338.93223.e8 · Cited by 452 · see citing works
Antiatherogenic small, dense HDL—guardian angel of the arterial wall?
Kontush, A., & Chapman, M. J. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0500 · Cited by 342 · see citing works
Brinton, E. A., Eisenberg, S., & Breslow, J. L. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114405 · Cited by 258 · see citing works
Chapman, M. J., Assmann, G., Fruchart, J., Shepherd, J., & Sirtori, C. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 255 · see citing works
Effects of Fibrates on Serum Metabolic Parameters
Elisaf, M. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000516 · Cited by 163 · see citing works
Self-citationRuotolo, G., Ericsson, C.-G., Tettamanti, C., Karpe, F., Grip, L., Svane, B., Nilsson, J. Å., Fairé, U. D., & Hamsten, A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00442-2 · Cited by 158 · see citing works
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
Fruchart, J., & Duriez, P. (2006) · Drugs of today · doi:10.1358/dot.2006.42.1.963528 · Cited by 132 · see citing works
Westman, E. C., Yancy, W. S., Olsen, M. K., Dudley, T., & Guyton, J. R. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.08.034 · Cited by 115 · see citing works
Orlistat Inhibits Dietary Cholesterol Absorption
Mittendorfer, B., Ostlund, R. E., Patterson, B. W., & Klein, S. (2001) · Obesity Research · doi:10.1038/oby.2001.79 · Cited by 114 · see citing works
The Role of Insulin Insensitivity and Hepatic Lipase in the Dyslipidaemia of Type 2 Diabetes
Baynes, C., Henderson, A. D., Anyaoku, V., Richmond, W., Hughes, C. L., Johnston, D. G., & Elkeles, R. S. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01652.x · Cited by 98 · see citing works
Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Georgoula, M., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75078 · Cited by 86 · see citing works
Self-citationFenofibrate: Metabolic and Pleiotropic Effects
Tsimihodimos, V., Miltiadous, G. A., Daskalopoulou, S. S., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161052773942 · Cited by 74 · see citing works
Self-citationMajali, K. A., Cooper, M. B., Staels, B., Luc, G., Taskinen, M., & Betteridge, D. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0092-4 · Cited by 58 · see citing works
A new sandwich enzyme immunoassay for measurement of plasma pre-β1-HDL levels
Miyazaki, O., Kobayashi, J., Fukamachi, I., Miida, T., Bujo, H., & Saito, Y. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32370-1 · Cited by 53 · see citing works
Guérin, M., Goff, W. L., Frisdal, É., Schneider, S., Milosavljevic, D., Bruckert, É., & Chapman, M. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030191 · Cited by 51 · see citing works
Analytical performance of a sandwich enzyme immunoassay for preβ1-HDL in stabilized plasma
Miida, T., Miyazaki, O., Nakamura, Y. K., Hirayama, S., Hanyu, O., Fukamachi, I., & Okada, M. (2003) · Journal of Lipid Research · doi:10.1194/jlr.d200025-jlr200 · Cited by 48 · see citing works
Musliner, T., Long, M., Forte, T., Nichols, A., Gong, E., Blanche, P. J., & Krauss, R. M. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41989-3 · Cited by 45 · see citing works
Secretion of pre-beta-migrating apoA-I by cynomolgus monkey hepatocytes in culture
Castle, C., Pape, M. E., Marotti, K. R., & Melchior, G. W. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42067-x · Cited by 40 · see citing works
Bezafibrate Increases Preβ1-HDL at the Expense of HDL 2b in Hypertriglyceridemia
Miida, T., Sakai, K., Ozaki, K., Nakamura, Y., Yamaguchi, T., Tsuda, T., Kashiwa, T., Murakami, T., Inano, K., & Okada, M. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.2428 · Cited by 37 · see citing works
Apical secretion of apolipoproteins from enterocytes.
Danielsen, E. M., Hansen, G. H., & Poulsen, M. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.120.6.1347 · Cited by 36 · see citing works
Alterations of high-density lipoprotein subclasses in endogenous hypertriglyceridemia
Gou, L., Fu, M., Xu, Y., Tian, Y., Yan, B., & Lu-chuan, Y. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.032 · Cited by 33 · see citing works
van Tol, A. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510151067866 · Cited by 28 · see citing works
Kinetics of preβ1 HDL and αHDL in type II diabetic patients
Chétiveaux, M., Lalanne, F., Lambert, G. C., Zaïr, Y., Ouguerram, K., & Krempf, M. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01586.x · Cited by 19 · see citing works
Filippatos, T. D., Kiortsis, D. N., Gazi, I. F., Liberopoulos, E. N., Georgoula, M., Elisaf, M., & Tselepis, A. D. (2006) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(06)82229-4 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Cardiology · doi:10.1159/000346463 · Cited by 749 · see citing works
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · see citing works
Self-citationNikolić, D., Katsiki, N., Montalto, G., Isenović, E. R., Mikhailidis, D. P., & Rizzo, M. (2013) · Nutrients · doi:10.3390/nu5030928 · Cited by 160 · see citing works
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136 · see citing works
Self-citationMouse Models of Experimental Autoimmune Uveitis
Caspi, R. R., Silver, P. B., Luger, D., Tang, J., Cortes, L. M., Pennesi, G., Mattapallil, M. J., & Chan, C. (2008) · Ophthalmic Research · doi:10.1159/000119871 · Cited by 118 · see citing works
Sahebkar, A., Simental‐Mendía, L. E., Reiner, Ž., Kovanen, P. T., Simental-Mendía, M. A., Bianconi, V., & Pirro, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.022 · Cited by 110 · see citing works
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Filippatos, T. D., Athyros, V. G., & Elisaf, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.907274 · Cited by 83 · see citing works
Self-citationFilippatos, T. D., Alexakis, K., Mavrikaki, V., & Mikhailidis, D. P. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06824-7 · Cited by 81 · see citing works
Self-citationLagos, K. G., Filippatos, T. D., Tsimihodimos, V., Gazi, I. F., Rizos, C. V., Tselepis, A. D., Mikhailidis, D. P., & Elisaf, M. (2008) · Lipids · doi:10.1007/s11745-008-3251-9 · Cited by 74 · see citing works
Self-citationZhao, B., Cui, Y., Fan, X., Qi, P., Liu, C., Zhou, X., & Zhang, X. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218543 · Cited by 69 · see citing works
Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Katsiki, N., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Vascular Pharmacology · doi:10.2174/15701611113119990131 · Cited by 66 · see citing works
Woudberg, N. J., Goedecke, J. H., Blackhurst, D., Frias, M. A., James, R. W., Opie, L. H., & Lecour, S. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0257-9 · Cited by 60 · see citing works
Milionis, H. J., Moutzouri, E., Kei, & Elisaf, M. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59 · see citing works
Self-citationTreatment of hyperlipidaemia with fenofibrate and related fibrates
Filippatos, T. D., & Milionis, H. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1599 · Cited by 57 · see citing works
Self-citationAslan, I., Kucuksayan, E., & Aslan, M. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-54 · Cited by 35 · see citing works
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Filippatos, T. D., Kei, A. A., Rizos, C. V., & Elisaf, M. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417724868 · Cited by 43 · see citing works
Self-citationFenofibrate and metabolic syndrome
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · see citing works
“4%) for HDLC [32-44] (see Fig.”
Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights
Westerveld, H. E., Hoogendoorn, M., de Jong, A. W. F., Goverde, A. J., Fauser, B. C. J. M., & Dallinga‐Thie, G. M. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.04.009 · Cited by 38 · see citing works
Agouridis, A. P., Rizos, C. V., Elisaf, M., & Filippatos, T. D. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.171 · Cited by 35 · see citing works
Self-citationNakou, E., Filippatos, T. D., Kiortsis, D. N., Derdemezis, C. S., Tselepis, A. D., Mikhailidis, D. P., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802548430 · Cited by 35 · see citing works
Self-citationFilippatos, T. D., Derdemezis, C. S., Voulgari, P. V., Tsimihodimos, V., Elisaf, M., Tselepis, A. D., & Drosos, A. A. (2013) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2012.745013 · Cited by 32 · see citing works
Self-citationPharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 29 · see citing works
Self-citationHDL Subclass Distribution Shifts with Increasing Central Adiposity
Woudberg, N. J., Lecour, S., & Goedecke, J. H. (2019) · Journal of Obesity · doi:10.1155/2019/2107178 · Cited by 27 · see citing works
Agouridis, A. P., Kostapanos, M. S., Tsimihodimos, V., Kostara, C. E., Mikhailidis, D. P., Bairaktari, E. T., Tselepis, A. D., & Elisaf, M. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02972.x · Cited by 25 · see citing works
Self-citationHigh density lipoprotein and cardiovascular diseases
Filippatos, T. D. (2013) · World Journal of Cardiology · doi:10.4330/wjc.v5.i7.210 · Cited by 25 · see citing works
Self-citationFilippatos, T. D., Rizos, E. C., Tsimihodimos, V., Gazi, I. F., Tselepis, A. D., & Elisaf, M. (2013) · Lipids · doi:10.1007/s11745-013-3787-1 · Cited by 26 · see citing works
Self-citationFenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Filippatos, T. D., & Elisaf, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.593509 · Cited by 25 · see citing works
Self-citationNakou, E. S., Filippatos, T. D., Agouridis, A. P., Kostara, C., Bairaktari, E. T., & Elisaf, M. S. (2010) · Lipids · doi:10.1007/s11745-010-3409-0 · Cited by 23 · see citing works
Self-citationFilippatos, T. D., Rizos, E. C., Gazi, I. F., Lagos, K. G., Agouridis, D., Mikhailidis, D. P., & Elisaf, M. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.38671 · Cited by 23 · see citing works
Self-citationInsulin resistance and lipid disorders
Miccoli, R., Keyzer, D. D., Penno, D. G., & Prato, D. S. D. (2008) · Future Lipidology · doi:10.2217/17460875.3.6.651 · Cited by 24 · see citing works
Safety considerations with fenofibrate/simvastatin combination
Filippatos, T. D., & Elisaf, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1056778 · Cited by 22 · see citing works
Self-citationA Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
Filippatos, T. D. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6394-0 · Cited by 22 · see citing works
Self-citationFuior, E. V., Zvintzou, E., Filippatos, T. D., Giannatou, K., Mparnia, V., Simionescu, M., Gafencu, A. V., & Kypreos, K. E. (2023) · Biomedicines · doi:10.3390/biomedicines11102696 · Cited by 22 · see citing works
Self-citationWoudberg, N. J., Goedecke, J. H., & Lecour, S. (2016) · Ethnicity & Disease · doi:10.18865/ed.26.4.553 · Cited by 20 · see citing works
Filippatos, T. D., Tsimihodimos, V., Kostapanos, M. S., Kostara, C. E., Bairaktari, E. T., Kiortsis, D. N., & Elisaf, M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.001 · Cited by 18 · see citing works
Self-citationCombinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism
Agouridis, A. P., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.4 · Cited by 16 · see citing works
Self-citationNakou, E. S., Filippatos, T. D., Liberopoulos, E. N., Tselepis, A. D., Kiortsis, D. N., Mikhailidis, D. P., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.10.1629 · Cited by 16 · see citing works
Self-citationHIV-related cardiovascular disease: any role for high-density lipoproteins?
Hudson, P., Woudberg, N. J., Kamau, F., Strijdom, H., Frias, M. A., & Lecour, S. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00445.2020 · Cited by 15 · see citing works
Maranghi, M., Hiukka, A., Badeau, R. M., Sundvall, J., Jauhiainen, M., & Taskinen, M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.018 · Cited by 14 · see citing works
Combination drug treatment in obese diabetic patients
Filippatos, T. D. (2010) · World Journal of Diabetes · doi:10.4239/wjd.v1.i1.8 · Cited by 11 · see citing works
Self-citationBu, X., Niu, D.-M., Wu, J., Yuan, Y., Song, J., & Wang, J. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-016-0394-1 · Cited by 10 · see citing works
Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors
Filippatos, T. D., Derdemezis, C. S., & Elisaf, M. (2009) · Clinical Lipidology · doi:10.2217/clp.09.25 · Cited by 10 · see citing works
Self-citationNiesor, E. J., Gauthamadasa, K., Silva, R. A. G. D., Suchánková, G., Kallend, D. G., Gylling, H., Asztalos, B. F., Damonte, E., Rossomanno, S., Abt, M., et al. (2013) · Lipids · doi:10.1007/s11745-013-3841-z · Cited by 9 · see citing works
Tsai, A. K., Steffen, B. T., Ordovás, J. M., Straka, R. J., Zhou, X., Hanson, N. Q., Arnett, D. K., & Tsai, M. Y. (2011) · Translational research · doi:10.1016/j.trsl.2011.01.014 · Cited by 7 · see citing works
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7 · see citing works
Self-citationFibratos: efectos farmacológicos
Jover, A., & Hernández‐Mijares, A. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(12)70009-8 · Cited by 2 · see citing works
Hypertension and Dyslipidemia in Patients with Pre-Diabetes
Tsimihodimos, V., & Florentin, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00013-2 · Cited by 1 · see citing works
Vozzi, F., Pelosi, G., Puntoni, M., Viglione, F., Rocchiccioli, S., Kusmic, C., Bernini, F., Marraccini, P., Trivella, M. G., & Parodi, O. (2014) · Open Journal of Molecular and Integrative Physiology · doi:10.4236/ojmip.2014.44006
Naltrexone/Bupropion ER for the treatment of obesity
Elisaf, M., Pappa, E. T., & Filippatos, T. D. (2017) · doi:10.23803/hja.v7i4.97.g60
Self-citationCurrent literature in diabetes
(2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.914
Parte I. Fibratos en prevención primaria y secundaria
(2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(16)30083-3
- Authors
- Filippatos, T. D., Liberopoulos, E. N., Kostapanos, M., Gazi, I. F., Papavasiliou, E. C., Kiortsis, D. N., Tselepis, A. D., & Elisaf, M. S.
- Affiliations
- University of Ioannina (GR)
- Corresponding author
- Elisaf, M. S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2007-04-24
- Volume
- 10
- Issue
- 6
- Pages
- 476-483
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2026020109
- Cited by
- 51
- References
- 29
- Citations by year
- 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 1 · 2014: 5 · 2013: 9 · 2012: 4
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- orlistat, fenofibrate, combination therapy, HDL subfractions, HDL cholesterol, small HDL particles, large HDL particles, metabolic syndrome, obesity, overweight
- MeSH terms
- Orlistat, Hypolipidemic Agents, Drug Therapy, Combination, Female, Greece, Humans, Lactones, Lipoproteins, HDL, Cholesterol, HDL, Male, Middle Aged, Obesity, Fenofibrate, Body Mass Index, Anti-Obesity Agents, Metabolic Syndrome, Overweight, High-Density Lipoproteins, Pre-beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
